Outcomes of six-dose high-dose cytarabine (HiDAC-6) as a salvage regimen for patients with relapsed/refractory acute myeloid leukemia (RR-AML).

被引：1
|
作者：
Veltri, Lauren Westfall [1 ]
Anders, Brandi [1 ]
Kanate, Abraham Sebastian [1 ]
Shillingburg, Alexandra [1 ]
Craig, Michael D. [1 ]
Cumpston, Aaron [1 ]
机构：
[1] West Virginia Univ, Morgantown, WV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e18508
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18508
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML).
    Nunnery, Sara
    Wang, Dorothy
    Tan, Marisela
    Fong, Richard
    Lo, Mimi Ming
    Olin, Rebecca L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable
    Wang, Amy Y.
    Weiner, Howie Lawrence
    Green, Margaret
    Larson, Richard A.
    Odenike, Olatoyosi
    Artz, Andrew
    Godley, Lucy A.
    Thirman, Michael J.
    Churpek, Jane E.
    Curran, Emily K.
    Pettit, Kristen
    Stock, Wendy
    Liu, Hongtao
    BLOOD, 2016, 128 (22)
  • [23] HIGH-DOSE CYTARABINE (HD-ARA-C) IN REFRACTORY AND RELAPSED ADULT ACUTE MYELOGENOUS LEUKEMIA (AML)
    HOFELER, H
    ANDERS, CU
    POPESCU, O
    HOFFKEN, K
    SCHMIDT, CG
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 209 - 209
  • [24] Limited phase I trial of sequential high dose cytarabine and clofarabine (HiDAC→CLOF) in relapsed or refractory acute myeloid leukemia.
    Powell, Bayard L.
    Lovato, James
    Kimbrough, Claire
    Lyerly, Susan
    Galloway-Daniels, Sonya
    Motley, Cathy
    Harrelson, Robin
    Keung, Yi Kong
    Thakuri, Mohan C.
    Molnar, Istvan
    Levitan, Denise
    Hurd, David Duane
    BLOOD, 2006, 108 (11) : 221B - 221B
  • [25] Outcome of etoposide and mitoxantrone for relapsed or refractory acute myeloid leukemia (RR-AML) in the modern era.
    Bowman, Zelia Ramone Karema
    Caddell, Ryan James
    Kanate, Abraham Sebastian
    Shillingburg, Alex
    Shah, Nilay Arvind
    Craig, Michael
    Cumpston, Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] MITOZANTRONE AND HIGH-DOSE CYTARABINE IN REFRACTORY ADULT ACUTE MYELOID-LEUKEMIA
    HIDDEMANN, W
    KREUTZMANN, H
    LUDWIG, WD
    AUL, HC
    DONHUIJSENANT, R
    LENGFELDER, E
    BUCHNER, T
    LANCET, 1985, 2 (8453): : 508 - 509
  • [27] G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Becker, Pamela S.
    Estey, Elihu
    Petersdorf, Stephen
    Storer, Barry E.
    Appelbaum, Frederick R.
    BLOOD, 2009, 114 (22) : 816 - 816
  • [28] High-dose cytarabine induction for acute myeloid leukemia
    Shepherd, JD
    Barnett, MJ
    Phillips, GL
    BLOOD, 1996, 88 (02) : 754 - 754
  • [29] Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG
    M Fiegl
    M Unterhalt
    W Kern
    J Braess
    K Spiekermann
    P Staib
    A Grüneisen
    B Wörmann
    D Schöndube
    H Serve
    A Reichle
    M Hentrich
    X Schiel
    C Sauerland
    A Heinecke
    C Rieger
    D Beelen
    W E Berdel
    T Büchner
    W Hiddemann
    Leukemia, 2014, 28 : 1001 - 1007
  • [30] Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.
    Karol, Seth E.
    Alexander, Thomas
    Das Gupta, Soumyasri
    Pounds, Stanley B.
    Canavera, Kristin
    Klco, Jeffery M.
    Lacayo, Norman James
    Pui, Ching-Hon
    Opferman, Joseph T.
    Rubnitz, Jeffrey E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345